132 related articles for article (PubMed ID: 26448330)
1. Hsp70 (HSPA1) Lysine Methylation Status as a Potential Prognostic Factor in Metastatic High-Grade Serous Carcinoma.
Jakobsson ME; Moen A; Davidson B; Falnes PØ
PLoS One; 2015; 10(10):e0140168. PubMed ID: 26448330
[TBL] [Abstract][Full Text] [Related]
2. BAG-1/SODD, HSP70, and HSP90 are potential prognostic markers of poor survival in node-negative breast carcinoma.
Davidson B; Valborg Reinertsen K; Trinh D; Reed W; Bøhler PJ
Hum Pathol; 2016 Aug; 54():64-73. PubMed ID: 27038683
[TBL] [Abstract][Full Text] [Related]
3. The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions.
Davidson B; Holth A; Hellesylt E; Tan TZ; Huang RY; Tropé C; Nesland JM; Thiery JP
Hum Pathol; 2015 Jan; 46(1):1-8. PubMed ID: 25455994
[TBL] [Abstract][Full Text] [Related]
4. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
[TBL] [Abstract][Full Text] [Related]
5. B7-H4 expression in ovarian serous carcinoma: a study of 306 cases.
Liang L; Jiang Y; Chen JS; Niu N; Piao J; Ning J; Zu Y; Zhang J; Liu J
Hum Pathol; 2016 Nov; 57():1-6. PubMed ID: 27349304
[TBL] [Abstract][Full Text] [Related]
6. The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma.
Cho D; Park H; Park SH; Kim K; Chung M; Moon W; Kang M; Jang K
J Ovarian Res; 2015 Feb; 8():2. PubMed ID: 25823848
[TBL] [Abstract][Full Text] [Related]
7. Survival differences in women with serous tubal, ovarian, peritoneal, and uterine carcinomas.
Usach I; Blansit K; Chen LM; Ueda S; Brooks R; Kapp DS; Chan JK
Am J Obstet Gynecol; 2015 Feb; 212(2):188.e1-6. PubMed ID: 25149685
[TBL] [Abstract][Full Text] [Related]
8. MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma.
Nymoen DA; Slipicevic A; Holth A; Emilsen E; Hetland Falkenthal TE; Tropé CG; Reich R; Flørenes VA; Davidson B
Hum Pathol; 2016 Aug; 54():74-81. PubMed ID: 27063471
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions.
Slipicevic A; Øy GF; Askildt IC; Holth A; Hellesylt E; Flørenes VA; Davidson B
Hum Pathol; 2009 Apr; 40(4):527-37. PubMed ID: 19121847
[TBL] [Abstract][Full Text] [Related]
10. Ovarian serous tumors of low malignant potential with nodal low-grade serous carcinoma.
Djordjevic B; Malpica A
Am J Surg Pathol; 2012 Jul; 36(7):955-63. PubMed ID: 22613998
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of neuroendocrine differentiation in high-grade serous ovarian carcinoma.
Taube ET; Denkert C; Pietzner K; Dietel M; Sehouli J; Darb-Esfahani S
Virchows Arch; 2015 Mar; 466(3):333-42. PubMed ID: 25522951
[TBL] [Abstract][Full Text] [Related]
12. Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma.
Onallah H; Catane LJ; Tropé CG; Hetland Falkenthal TE; Reich R; Davidson B
Virchows Arch; 2018 Oct; 473(4):463-470. PubMed ID: 30032361
[TBL] [Abstract][Full Text] [Related]
13. Mortalin is a distinct bio-marker and prognostic factor in serous ovarian carcinoma.
Xu M; Jin T; Chen L; Zhang X; Zhu G; Wang Q; Lin Z
Gene; 2019 May; 696():63-71. PubMed ID: 30776464
[TBL] [Abstract][Full Text] [Related]
14. TSAP6 is a novel candidate marker of poor survival in metastatic high-grade serous carcinoma.
Broner EC; Tropé CG; Reich R; Davidson B
Hum Pathol; 2017 Feb; 60():180-187. PubMed ID: 27825812
[TBL] [Abstract][Full Text] [Related]
15. Exosome-derived miRNAs and ovarian carcinoma progression.
Vaksman O; Tropé C; Davidson B; Reich R
Carcinogenesis; 2014 Sep; 35(9):2113-20. PubMed ID: 24925027
[TBL] [Abstract][Full Text] [Related]
16. HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival.
Stavnes HT; Holth A; Don T; Kærn J; Vaksman O; Reich R; Trope' CG; Davidson B
Gynecol Oncol; 2013 May; 129(2):358-63. PubMed ID: 23438671
[TBL] [Abstract][Full Text] [Related]
17. A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma.
Dong F; Davineni PK; Howitt BE; Beck AH
Cancer Epidemiol Biomarkers Prev; 2016 Nov; 25(11):1511-1516. PubMed ID: 27496093
[TBL] [Abstract][Full Text] [Related]
18. APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival.
Tuft Stavnes H; Nymoen DA; Hetland Falkenthal TE; Kærn J; Tropé CG; Davidson B
Am J Clin Pathol; 2014 Jul; 142(1):51-7. PubMed ID: 24926085
[TBL] [Abstract][Full Text] [Related]
19. Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance.
Hetland TE; Hellesylt E; Flørenes VA; Tropé C; Davidson B; Kærn J
Hum Pathol; 2011 Jul; 42(7):1019-26. PubMed ID: 21315408
[TBL] [Abstract][Full Text] [Related]
20. HOXA11 DNA methylation--a novel prognostic biomarker in ovarian cancer.
Fiegl H; Windbichler G; Mueller-Holzner E; Goebel G; Lechner M; Jacobs IJ; Widschwendter M
Int J Cancer; 2008 Aug; 123(3):725-9. PubMed ID: 18478570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
